Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (Q43457128)
Jump to navigation
Jump to search
scientific article published on 10 November 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia |
scientific article published on 10 November 2014 |
Statements
1 reference
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (English)
1 reference
Hermann Einsele
1 reference
Dieter Hoelzer
1 reference
Monika Brüggemann
1 reference
Gerhard Zugmaier
1 reference
Albrecht Reichle
1 reference
Max S Topp
1 reference
Petra Klappers
1 reference
Matthias Stelljes
1 reference
Svenja Neumann
1 reference
Andreas Viardot
1 reference
Reinhard Marks
1 reference
Helmut Diedrich
1 reference
Christoph Faul
1 reference
Heinz-August Horst
1 reference
Dorothea Wessiepe
1 reference
Chris Holland
1 reference
Shilpa Alekar
1 reference
Noemi Mergen
1 reference
Ralf C Bargou
1 reference
10 November 2014
1 reference
1 reference
32
1 reference
36
1 reference
4134-4140
1 reference
Identifiers
1 reference
1 reference